Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies
Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.
As part of the bio/pharmaceutical industry’s global response efforts for COVID-19, companies are also racing to develop therapies to treat COVID-19 in parallel with vaccine development efforts. As of Sept. 25, 2020, more than 590 drug development programs are in planning stages, and FDA has reviewed more than 310 trials, as of the end of August 2020, of potential COVID-19 therapies. The agency also published industry guidance in September 2020 around assessing symptoms in individuals undergoing clinical trials for COVID-19 therapies.
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 3–8
Citation
When referring to this article, please cite it as F. Mirasol, “Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies," BioPharm International Regulatory Sourcebook eBook (October 2020).
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
